《美股業績》Crocs(CROX.US)第四季獲利預測低於預期 股價挫7%
鞋類製造商Crocs(CROX.US)股價周四下跌逾7%,公司發布的第四季度盈利預測低於分析師預期,儘管其第三季度業績超出預期。
該公司第三季淨利潤按年升4.5%至1.77億美元,相當於攤薄每股盈利2.87美元。調整後利潤總計為每股3.25美元,高於市場預期的每股3.10美元。期內營收增長6.2%至10.5億美元,高於預期的10.3億美元。
展望未來,Crocs預計第四季經調整每股攤薄盈利為2.05至2.35美元,低於分析師預期的2.78美元。
該公司表示,其HeyDude品牌將面臨更多挑戰,其最新的2023年營收預測為4%至6%增長,低於夏季時14%至18%的成長預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.